Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in operable head and neck cancer
NCT03153982Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jun 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of California, San Francisco. Primary endpoint: Proportional Percent Change in Tumor Size by Group up to 4 weeks. Started Jun 2018; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03153982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153982.